Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer

M Mortazavi, F Moosavi, M Martini, E Giovannetti… - Critical reviews in …, 2022 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses among all
malignancies. PI3K/AKT/mTOR signaling pathway, a main downstream effector of KRAS is …

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer

S Casacuberta-Serra, Í González-Larreategui… - … and Targeted Therapy, 2024 - nature.com
RAS and MYC rank amongst the most commonly altered oncogenes in cancer, with RAS
being the most frequently mutated and MYC the most amplified. The cooperative interplay …

The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients

A Osipov, O Nikolic, A Gertych, S Parker, A Hendifar… - Nature cancer, 2024 - nature.com
Contemporary analyses focused on a limited number of clinical and molecular biomarkers
have been unable to accurately predict clinical outcomes in pancreatic ductal …

Multi-targeting liposomal codelivery of cisplatin and rapamycin inhibits pancreatic cancer growth and metastasis through stromal modulation

W Zhu, H Yu, M Jia, C Lin, Z Yuan, X Tan… - International Journal of …, 2023 - Elsevier
Pancreatic cancer treatment faces challenges due to drug resistance as well as liver
metastasis. As a new strategy for treating pancreatic cancer, combination therapy is now …

KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas

AC Diehl, LM Hannan, DB Zhen, AL Coveler… - The …, 2022 - academic.oup.com
Background KRAS variant alleles may have differential biological properties which impact
prognosis and therapeutic options in pancreatic ductal adenocarcinomas (PDA). Materials …

Targeting Pancreatic Cancer with Novel Plumbagin Derivatives: Design, Synthesis, Molecular Mechanism, In Vitro and In Vivo Evaluation

S Awale, H Baba, ND Phan, MJ Kim… - Journal of Medicinal …, 2023 - ACS Publications
Pancreatic tumors grow in an “austerity” tumor microenvironment characterized by nutrient
deprivation and hypoxia. This leads to the activation of adaptive pathways in pancreatic …

Synthesis and structure–activity analysis of icaritin derivatives as potential tumor growth inhibitors of hepatocellular carcinoma cells

J Li, S Shen, Z Liu, H Zhao, S Liu, Q Liu… - Journal of Natural …, 2023 - ACS Publications
The prenylated flavonoid icaritin (ICT, 1), a new drug for treating advanced hepatocellular
carcinoma (HCC), was selected as a template to develop more potent inhibitors. An initial …

Reshaping the pancreatic cancer microenvironment at different stages with chemotherapy

M Peng, Y Ying, Z Zhang, L Liu, W Wang - Cancers, 2023 - mdpi.com
Simple Summary Reshaped pancreatic tumor microenvironment by chemotherapy,
ultimately preventing or promoting tumor progression, is presented by the alteration of …

Prognostic stratification based on HIF-1 signaling for evaluating hypoxic status and immune infiltration in pancreatic ductal adenocarcinomas

H Zhuang, S Wang, B Chen, Z Zhang, Z Ma… - Frontiers in …, 2021 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) has a hypoxic and desmoplastic tumor
microenvironment (TME), leading to treatment failure. We aimed to develop a prognostic …

GSK2126458 has the potential to inhibit the proliferation of pancreatic cancer uncovered by bioinformatics analysis and pharmacological experiments

Y Feng, Y Jiang, F Hao - Journal of translational medicine, 2021 - Springer
Background Pancreatic cancer is one of the most serious digestive malignancies. At present,
there is an extreme lack of effective strategies in clinical treatment. The purpose of this study …